ST Jingji suddenly became popular! 48 institutions conducted research! The company states that it has technical reserves for space photovoltaics.

This week (January 26 – January 30), a total of 113 listed companies received institutional investor research. In terms of profitability effects, Kechuan Technology, Hason Shares, and Runtu Shares all increased by over 30%, while Liancheng CNC, Shenda Resources, Yamaton, and Qipai Technology all rose by more than 15%. Among them, Hason Shares hit the 3rd board on the 5th, and Runtu Shares hit the 2nd board on the 3rd.

Regarding popular research stocks, no company was surveyed by over 100 institutions this week. Shanghai Bank, TainKang, Bee Helper, ST Jingji, LiuGong, and Hailide attracted significant institutional attention this week.

Shanghai Bank: Focus on Interest Margin Changes

Shanghai Bank hosted 75 institutional investors this week, the highest among all companies, with a focus on its new year credit issuance plan and current deployment status. An executive from Shanghai Bank explained that the bank proactively launched its “Red Opening” credit work plan, optimizing resource allocation and policy support. The quantity and quality of “Red Opening” project reserves have improved compared to previous years. In retail credit, the bank focuses on “housing ecology” and “car ecology” to increase deployment; in housing mortgage loans, it continues to leverage regional advantages to expand mortgage credit supply; in auto consumer loans, it relies on policies like interest subsidies for personal consumption loans, with new energy vehicles as a key focus.

Regarding future interest margin changes, Shanghai Bank stated that on the asset side, the LPR (Loan Prime Rate) is expected to have room for further decline by 2026, with the re-pricing effect of existing assets continuing to release, leading to a continued decline in yield on interest-earning assets. On the liability side, deposit costs are expected to decrease with the LPR, but considering market competition, the pricing of newly attracted deposits may still decrease less than that of new loans, so net interest margin is expected to decline slightly.

TainKang: Future Performance Expected to Explode

Pharmaceutical company TainKang was surveyed by 57 institutions this week. The company has several blockbuster products approved this year and next, with institutional focus on its commercialization strategies. Recently, TainKang announced that its wholly owned subsidiary’s lidocaine and prilocaine aerosol has been accepted, marking a key progress in its R&D and industrialization in the field of sexual health drugs.

TainKang stated during the survey that for specific products, the compound sodium sulfate tablets will be quickly promoted into medical insurance after approval; the finasteride-tadalafil compound capsules have initiated insurance-related work. Although this product is a generic drug, it is likely to be a proprietary product in the next 4-5 years, with significant clinical advantages—faster symptom relief for prostate hyperplasia compared to single drugs like finasteride, with obvious effects in 2-4 weeks. The company will continue to promote its brand and is expected to become another blockbuster product for TainKang.

Additionally, TainKang recently disclosed its revenue targets for 2026–2028 as 1 billion, 1.5 billion, and 2 billion yuan, respectively, with profit targets of 300 million, 500 million, and 800 million yuan. Institutions asked how these revenue and profit goals will be broken down and achieved.

TainKang responded that, on one hand, its existing products, such as sexual health drugs “Aiting Jiu,” ophthalmic drugs “Woliting,” and traditional Chinese medicine, will maintain stable income; on the other hand, several core products will be approved or filed for approval successively. As core products like the domestic first imitation of finasteride-tadalafil compound capsules (“Aiting Lie”), lidocaine and prilocaine aerosol (domestic first imitation), compound sodium sulfate tablets (domestic first imitation), and stomach and intestinal pills (domestic exclusive) are approved and launched, the company’s revenue in 2026 will see significant growth, with explosive growth expected in 2027 and 2028.

IT service company Bee Helper was also surveyed by 57 institutions this week. The company has laid out in AI applications and commercial aerospace, with institutions focusing on its aerospace internet layout and its recent AI smart home solutions.

Bee Helper explained that the company highly values the development opportunities in commercial aerospace and aerospace internet, explicitly positioning them as the fourth growth curve. Its aerospace internet layout mainly focuses on aircraft communication connectivity and passenger services. After the maturity of aerospace internet business, the company will continue to follow the development of low-orbit satellites, promoting technology evolution from high-orbit to low-orbit, gradually building a complete integrated communication capability and service scenario for air, ground, and space.

ST Jingji: Technical Reserve for Space Photovoltaics

High-end intelligent complete equipment company ST Jingji (000821) was surveyed by 48 institutions this week. During the survey, ST Jingji stated that it has made significant breakthroughs in the North American market, becoming a core equipment supplier there, with successful delivery of photovoltaic module equipment to multiple clients.

According to ST Jingji, its competitive advantages in North America mainly include three aspects: first, high market share, with a significant share of module assembly lines and lamination equipment; second, localized services, with technical service centers and warehouses in the US providing quick after-sales support and spare parts; third, diverse customer structure, including Chinese-funded enterprises with factories in the US, Fortune 500 companies, and well-known local photovoltaic manufacturers.

Recently, Tesla founder Elon Musk proposed to promote the construction of space solar energy AI data centers at Davos, with space photovoltaics as a core energy supply method gaining attention. ST Jingji revealed during the survey that the company has conducted technical reserves in space photovoltaics, attracting key institutional attention.

It is understood that ST Jingji is one of the earliest listed companies in China focusing on perovskite equipment R&D and industrialization, starting its layout in 2020. The company believes perovskite is the next-generation technology route, with a complete R&D production line built in-house, rich experience in full-line delivery, and deep cooperation with industry-leading clients, continuously advancing technology and process reserves.

“Regarding space photovoltaics, we believe this is an important and forward-looking application of perovskite technology. Its core needs are in making batteries lightweight and flexible, and in coping with extreme space environments. The company has conducted technical reserves in this area, such as developing roll-to-roll flexible production equipment and vertical deposition equipment suitable for ultra-thin glass coating, to meet future space photovoltaic requirements for weight, foldability, and reliability,” said ST Jingji during the survey.

(Source: Securities Times · e Company)